Soon, rheumatologists may have another drug to offer their patients with refractory rheumatoid arthritis (RRA) for whom effective and safe treatment remains challenging. A study published in the New England Journal of Medicine shows that patients with RRA treated with once-daily baricitinib in a 4 mg dose had a significant clinical improvement in symptoms of…
Search results for: Big data
2016 ACR Distinguished Fellows Award Winners Discuss Early Career Contributions to Rheumatology
For they’re some very good fellows … no, seriously. They are this year’s recipients of the ACR Distinguished Fellows Awards. The Rheumatologist spoke with them about their burgeoning contributions to Advancing Rheumatology! ACR Distinguished Fellow Awards Eric Allenspach, MD, PhD Acting Assistant Professor, Seattle Children’s Hospital, Seattle Background: Dr. Allenspach seeks to understand the genetic basis…
New ACR President Dr. Sharad Lakhanpal Recalls Road to Leadership, Outlines Goals for 2017
It is a great honor to serve you as the 80th president of the American College of Rheumatology (ACR). The ACR is a leader in the world of rheumatology. Therefore, with this privilege also comes enormous responsibility. A Brief History of the ACR The first efforts to study and control the rheumatic diseases in the…
2016 ARHP Award Winners Discuss Their Contributions to Rheumatology
If you thought the presidential election was a tough choice, imagine selecting this year’s slate of ACR/ARHP award winners. At the 2016 ACR/ARHP Annual Meeting in Washington this November, the ACR and the ARHP honored a group of distinguished individuals who have made significant contributions to rheumatology research, education and patient care. In this issue,…
Benchmark 2017 Healthcare.gov Premiums Up 25%
(Reuters)—The average premium for benchmark 2017 Obamacare insurance plans sold on Healthcare.gov rose 25% compared with 2016, according to the U.S. government on Monday, the biggest increase since the insurance first went on sale in 2013 for the following year. The average monthly premium for the benchmark plan is rising to $302 from $242 in…
As Role of Kinase Inhibitors in Rheumatic Disease Treatment Expands, Experts Review Therapy’s Failures, Successes
LONDON—Kinase inhibitors’ profile in the world of rheumatic disease therapy is growing, and they are probably going to play an even larger and more central role as time goes on, experts said at the Annual Congress of the European League Against Rheumatism (EULAR) 2016. But Gary S. Firestein, MD, director of the Clinical and Translational…
How to Get Your EHR Up … & Keep It Running
Implementing a new electronic health record (EHR) system is no easy task—and one that a physician shouldn’t tackle alone. From the onset, you need to get buy-in from your practice’s colleagues. To do this, designate a physician champion to take charge of the effort. “This is a challenging position, because it’s difficult to convince people…
Diagnostic Criteria, Classification Lacking for Vasculitis; New Research in Treatment for Systemic Sclerosis
LONDON—Despite the detailed terminology for describing vasculitis established by the Chapel Hill Consensus (CHC) in 2012, the field badly needs better classification and diagnostic criteria for the group of diseases, an expert said in a presentation at the Annual Congress of the European League Against Rheumatism (EULAR 2016). It’s a topic that is now being…
Possible Impact of Biosimilar Infliximab on U.S. Market in Prescriptions, Pricing
The use of biosimilars for rheumatology in the U.S. became a reality when the U.S. Food and Drug Administration (FDA) approved Inflectra (infliximab-dyyb), a biosimilar to Remicade (infliximab), in April. What this may mean is increased competition among drug companies with regard to pricing and, therefore, potentially lower costs for U.S. patients, according to Seoyoung…
Conservative vs. Surgical: What Influences OA Treatment Choices?
Prior research has found that the use of surgery to treat osteoarthritis is increasing, while more conservative treatments, such as physical therapy, are underused. This disparity drove researchers to examine what influences a patient’s treatment choice. They found that a treatment’s characteristics—including a patient’s expectations for effectiveness and risk—affect decision making. Other influences: personal investment and circumstances, as well as support and advice from social networks and healthcare providers…
- « Previous Page
- 1
- …
- 30
- 31
- 32
- 33
- 34
- …
- 51
- Next Page »